Partial jejunal diversion using an incisionless magnetic anastomosis system: 1-year interim results in patients with obesity and diabetes

Machytka, Evžen; Bužga, Marek; Zonča, P; Lautz, David B.; Ryou, Marvin; Simonson, Donald C.; Thompson, Christopher C.

doi:10.1016/j.gie.2017.07.009

Cited by 115 publications

(86 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One further intestinal device is the incisionless magnetic anastomosis system (IMAS) (GI Windows) that allows a partial jejunal to ileal diversion by endoscopic placement of self‐assembling magnets that create a side to side compression anastomosis (Figure 3). The endoscopically‐delivered magnets create the proximal end of the anastomosis approximately 100 cm below the ligament of Treitz, whether the distal end of the anastomosis is approximately 100 cm upstream from the ileocecal junction 45 . In a single‐arm first‐in‐human pilot study evaluating 10 obese diabetic patients, the use of IMAS led to a significant reduction of excess body weight, glycated hemoglobin and liver enzymes 45 …”

Section: Duodenal Devicesmentioning

confidence: 99%

“…The endoscopically‐delivered magnets create the proximal end of the anastomosis approximately 100 cm below the ligament of Treitz, whether the distal end of the anastomosis is approximately 100 cm upstream from the ileocecal junction 45 . In a single‐arm first‐in‐human pilot study evaluating 10 obese diabetic patients, the use of IMAS led to a significant reduction of excess body weight, glycated hemoglobin and liver enzymes 45 …”

Section: Duodenal Devicesmentioning

confidence: 99%

See 1 more Smart Citation

Endoscopic bariatric and metabolic therapies for non‐alcoholic fatty liver disease: Evidence and perspectives

Salomone¹,

Sharaiha

Boškoski

2020

Liver International

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease in industrialized countries because of the worldwide epidemic of obesity. Beyond metabolic complications, a subset of patients with NAFLD develop non-alcoholic steatohepatitis (NASH) with fibrosis, which is emerging as a leading cause of liver transplantation due to progression to cirrhosis and cancer. For these reasons, NAFLD is considered a public health burden. In recent years endoscopic bariatric and metabolic therapies (EBMT) have emerged as safe and effective for the treatment of obesity and type 2 diabetes mellitus. EBMT include gastric and duodenal devices and techniques such as intragastric balloons, endoscopic sleeve gastroplasty, endoscopic small bowel by-pass and duodenal mucosal resurfacing. Observational studies and pilot trials have revealed beneficial effects of EBMT on NAFLD as assessed by noninvasive parameters or histology. In this review we summarise current evidence for the efficacy and safety of EBMT in obese patients with NAFLD and examine future clinical applications. K E Y W O R D S bariatric endoscopy, duodenal mucosal resurfacing, endoscopic sleeve gastroplasty, intragastric balloon, NAFLD, obesity How to cite this article: Salomone F, Sharaiha RZ, Boškoski I. Endoscopic bariatric and metabolic therapies for nonalcoholic fatty liver disease: Evidence and perspectives. Liver

show abstract

Section: Duodenal Devicesmentioning

confidence: 99%

Section: Duodenal Devicesmentioning

confidence: 99%

Endoscopic bariatric and metabolic therapies for non‐alcoholic fatty liver disease: Evidence and perspectives

Salomone¹,

Sharaiha

Boškoski

2020

Liver International

View full text Add to dashboard Cite

show abstract

“…The patients had 14.6% TBWL and a mean decrease in HbA1c of 1.9% at 1 year. The major side effect of the procedure was diarrhea, and one serious adverse event occurred that was unrelated to the study device . Further data are needed to assess this novel procedure.…”

Section: Small Bowel Therapiesmentioning

confidence: 99%

Endoscopic bariatric and metabolic therapies: Another tool for the management of diabetes and obesity

Chablaney

Kumta

2019

Journal of Diabetes

View full text Add to dashboard Cite

Endoscopic bariatric and metabolic therapies (EBMTs) have sparked significant interest as minimally invasive therapeutic options for weight loss. Although bariatric surgery remains an effective option for sustained weight loss and improvement in the metabolic syndrome, access and utilization are limited. Various EBMTs have been designed to emulate the physiologic effects of established surgical interventions, including space‐occupying and non‐space‐occupying gastric therapies, gastric remodeling procedures, and small bowel therapies. This review discusses the safety and efficacy of available US Food and Drug Administration‐approved minimally invasive endoscopic bariatric interventions, as well as those currently under investigation. In addition, the role of endoscopic revision after failed surgical intervention is discussed.

show abstract

“…Two hypotheses have been proposed to explain the effect of endoluminal sleeves on T2DM. The “foregut hypothesis” proposes that the exclusion of the “foregut”, duodenum and proximal jejunum, and the accelerated delivery of poorly digested nutrients to the “hindgut” possibly prevent secretion of a putative signal that promotes insulin resistance and T2DM [ 7 - 10 ]. The “hindgut hypothesis” assumes that diabetes control results from the accelerated delivery of nutrients to the distal intestine, enhancing a physiological signal that improves glucose metabolism and weight loss by accentuation of an “ileal brake” [ 11 - 14 ].…”

Section: Endoluminal Sleevesmentioning

confidence: 99%

Small Bowel Endoscopic Bariatric Therapies

Gong

Kim

2018

Clin Endosc

View full text Add to dashboard Cite

Endoscopic bariatric therapies that emulate some of the principles of bariatric surgery have been developed as a less invasive option for the treatment of obesity and related comorbidities. Small bowel endoscopic bariatric therapies include bypass sleeves, incisionless anastomosis systems, and duodenal mucosal resurfacing. Clinical experience with small bowel devices suggests that endoscopic bariatric procedures can be safely implemented and that these devices are effective for both weight loss and metabolic improvement. Although the mechanisms behind these effects should be further elucidated, endoscopic bariatric therapies may be more effective and safer adjunctive interventions than lifestyle modifications and pharmacological regimens for patients with obesity or obesity-related comorbidities.

show abstract

Partial jejunal diversion using an incisionless magnetic anastomosis system: 1-year interim results in patients with obesity and diabetes

Cited by 115 publications

References 21 publications

Endoscopic bariatric and metabolic therapies for non‐alcoholic fatty liver disease: Evidence and perspectives

Endoscopic bariatric and metabolic therapies for non‐alcoholic fatty liver disease: Evidence and perspectives

Endoscopic bariatric and metabolic therapies: Another tool for the management of diabetes and obesity

Small Bowel Endoscopic Bariatric Therapies

Contact Info

Product

Resources

About